RECRUITING

Expression of Stress Markers During Meth Treatment (EXPRESS+)

Talk to us

Conditions

Substance-Related DisordersHIV

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.

Official Title

Expression of Stress Markers in MSM Living With HIV Receiving Contingency Management for Methamphetamine Use Disorder

Quick Facts

Study Start:2022-09-01
Study Completion:2026-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05558345

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Assigned male sex at birth
  2. 2. 18 to 45 years of age
  3. 3. Reports having sex with men in the past 12 months.
  4. 4. HIV-positive (confirmed by certification or by HIV rapid test)
  5. 5. Has an HIV care provider (last seen in the past 12 months)
  6. 6. Has a current antiretroviral prescription
  7. 7. Meets the DSM-5 criteria for methamphetamine use disorder using SCID-5
  8. 8. Urine test is positive for methamphetamine within 30 days of their screening visit
  9. 9. Seeking treatment for methamphetamine use disorder.
  10. 10. Ability to attend twice weekly appointments for drug testing and treatment
  11. 1. Assigned male sex at birth
  12. 2. 18 to 45 years of age
  13. 3. Reports having sex with men in the past 12 months.
  14. 4. HIV-positive (confirmed by certification or by HIV rapid test)
  15. 5. Has an HIV care provider (last seen in the past 12 months)
  16. 6. Has a current antiretroviral prescription
  1. 1. Identifies as (cis- or transgender) female
  2. 2. Reports another current or past substance use disorder
  3. 3. Reports being in another intervention or clinical trial for substance use
  4. 4. Positive test for opioids, cocaine, and/or MDMA
  5. 1. Identifies as (cis- or transgender) female
  6. 2. Positive test for methamphetamine, opioids, cocaine, and/or MDMA.
  7. 3. Reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months
  8. 4. Reports past or current substance use disorder

Contacts and Locations

Study Contact

Michael J Li, PhD
CONTACT
3107948530
mjli@mednet.ucla.edu

Principal Investigator

Michael J Li, PhD
PRINCIPAL_INVESTIGATOR
UCLA Department of Family Medicine

Study Locations (Sites)

UCLA Vine Street Clinic
Los Angeles, California, 90038
United States

Collaborators and Investigators

Sponsor: University of California, Los Angeles

  • Michael J Li, PhD, PRINCIPAL_INVESTIGATOR, UCLA Department of Family Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-01
Study Completion Date2026-03-31

Study Record Updates

Study Start Date2022-09-01
Study Completion Date2026-03-31

Terms related to this study

Additional Relevant MeSH Terms

  • Substance-Related Disorders
  • HIV